NCT01756118 2023-02-16
A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia
Goethe University
Phase 1 Completed
Clinical Trials
6 trialsNCT01856101 2019-04-10
BEZ235
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Terminated
NCT01508104 2017-08-23
Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
University of Cincinnati
Phase 1 Terminated
NCT01248494 2016-07-25
PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Completed
NCT01453595 2016-02-29
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT01343498 2015-05-01
Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed